Displaying 961 - 980 of 1552
FTC Testifies on Importance of Competition and Antitrust Enforcement to Lower-Cost, Higher-Quality Health Care
Commission Approves FY 2008 HSR Premerger Notification Report; FTC Approves Final Consent Order in Matter Concerning Alta Bates Medical Group
Alta Bates Medical Group, Inc.
Alta Bates Medical Group, Inc., a 600-physician independent practice association serving the Berkeley and Oakland, California, area, settleed Commission charges that it violated federal antitrust law by fixing prices charged to health care insurers. The consent order prohibits Alta Bates from collectively negotiating fee-for-service reimbursements and engaging in related anticompetitive conduct. In addition to price-fixing of fee-for-service reimbursements, the FTC’s complaint alleges an unlawful concerted refusal to deal.
FTC Issues Interim Report on "Authorized Generic" Drugs
FTC Chairman Leibowitz: Eliminating Pay-for-Delay Pharmaceutical Settlements Would Save Consumers $3.5 Billion Annually
CSL Limited, a corporation, and Cerberus-Plasma Holdings, LLC, In the Matter of
The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune globulin (Ig), Albumin, Rho-D, and Alpha-1. These therapies are used to treat patients suffering from illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, alpha-1 antitrypsin disease, and hemolytic disease of the newborn. In approving the administrative complaint seeking to block the deal, the Commission also authorized the staff to seek a preliminary injunction in federal district court in Washington, D.C., to stop the transaction pending completion of the administrative trial. Following the FTC's lawsuit to block the transaction, CSL Limited announced that it would not proceed with its proposed acquisition.
FTC Testifies on "Competition Issues and Follow-on Biologic Drugs"
FTC Releases Report on Follow-on Biologic Drug Competition
Statement of the FTC's Bureau of Competition Regarding the Announcement that CSL Will Not Proceed with its Proposed Acquisition of Talecris Biotherapeutics
Chairman, Commissioners Issue Statement on Endocare, Inc.s Announcement That it has Terminated its Merger Agreement with Galil Medical Ltd.
FTC Settles Price-Fixing Charges Against San Francisco Bay Area Doctors Group
FTC Testifies in Support of Bill Banning Pay-for-Delay Settlements Between Brand and Generic Drug Companies
FTC Authorizes Suit To Stop CSLs Proposed $3.1 Billion Acquisition of Talecris Biotherapeutics
FTC Staff Advises Louisiana Legislature That Amended Bill Would Further Restrict Competition to Provide Dental Care to States Most Vulnerable Children
FTC Staff Advises Louisiana Legislature That Bill Would Restrict Competition to Provide Dental Care to the State's Underserved Children; At FTC's Request, District Court Halts Illegal Operations of Federal Loan Modification Law Center
FTC Staff Advises Maryland Physician-Hospital Organization That it Will Not Recommend Antitrust Challenge to Proposal to Provide Member Physicians Services Through Clinical Integration Program
Displaying 961 - 980 of 1552